TRIUMPH program trial design overview — all Phase 3 arms
Pinned because it affects plans people have already made, not because it is dramatic. Everything below is what is confirmed as of today.
This post is the record, and it will be edited as things change — with the change noted rather than substituted. If you have something firmer than what is here, a document or a date or a first-hand account, post it and it goes in with credit.
Read it this way:
- What is stated is confirmed; what is uncertain is marked as uncertain
- Anything time-sensitive is worth verifying yourself before you act on it
- The replies below carry the corrections, so read them before asking
Nothing here is advice about your situation, and the situation is still moving.
TrialTracker_MD said:TRIUMPH program trial design overview — all Phase 3 arms Pinned because it affects plans people have already made, not because it is dramatic.
Fair, but phase 2 tolerability figures rarely survive contact with phase 3 scale. Triple agonism means three receptor systems generating adverse events, and the dropout column is the one I would read first when the larger trials report.
TrialTracker_MD said:TRIUMPH program trial design overview — all Phase 3 arms Pinned because it affects plans people have already made, not because it is dramatic.
I would rather people stopped quoting the 24% as if it were a licensed outcome. It is a phase 2 result in a few hundred participants with no cardiovascular endpoint and no long-term safety data, and this board has a habit of treating pipeline numbers as settled.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemThis one has a reasonably settled answer, so here it is. The phase 2 numbers were about 24% mean weight loss at 48 weeks on the top dose, with the curve still descending at the end of the study. A curve that has not flattened is a real finding, but it also means the true plateau is unknown, and phase 2 populations are small and selected.
InsuranceTom said:Fair, but phase 2 tolerability figures rarely survive contact with phase 3 scale.
Agreed, and subgroup analyses deserve particular suspicion. With enough subgroups something is significant by chance, and pre-registered subgroups are a different animal from ones found afterwards.
I would rather be corrected than agreed with, if it comes to it.